Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DWTX NASDAQ:IMA NASDAQ:KLTO NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$4.85-1.1%$4.86$1.62▼$29.28$9.26M1.791.54 million shs25,142 shsIMAImageneBio$8.50+1.8%$13.86$7.95▼$23.28$34.17M0.4918,302 shs112,539 shsKLTOKlotho Neurosciences$0.56-2.6%$0.88$0.11▼$3.91$34.07M10.7415.83 million shs792,259 shsXFORX4 Pharmaceuticals$3.28+8.0%$2.55$1.35▼$26.83$37.17M0.611.58 million shs577,936 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics+0.41%+0.82%-7.55%+2.08%+489,999,900.00%IMAImageneBio-2.00%-6.29%-43.20%-49.21%-58.33%KLTOKlotho Neurosciences-3.47%+9.70%-27.51%-62.00%+56,999,900.00%XFORX4 Pharmaceuticals-5.30%-10.32%+22.09%+7.80%-85.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$4.85-1.1%$4.86$1.62▼$29.28$9.26M1.791.54 million shs25,142 shsIMAImageneBio$8.50+1.8%$13.86$7.95▼$23.28$34.17M0.4918,302 shs112,539 shsKLTOKlotho Neurosciences$0.56-2.6%$0.88$0.11▼$3.91$34.07M10.7415.83 million shs792,259 shsXFORX4 Pharmaceuticals$3.28+8.0%$2.55$1.35▼$26.83$37.17M0.611.58 million shs577,936 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics+0.41%+0.82%-7.55%+2.08%+489,999,900.00%IMAImageneBio-2.00%-6.29%-43.20%-49.21%-58.33%KLTOKlotho Neurosciences-3.47%+9.70%-27.51%-62.00%+56,999,900.00%XFORX4 Pharmaceuticals-5.30%-10.32%+22.09%+7.80%-85.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDWTXDogwood Therapeutics 3.00Buy$10.00106.40% UpsideIMAImageneBio 2.50Moderate Buy$35.50317.65% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/AXFORX4 Pharmaceuticals 3.00Buy$34.17941.03% UpsideCurrent Analyst Ratings BreakdownLatest DWTX, XFOR, IMA, and KLTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025XFORX4 PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $9.008/13/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$7.00 ➝ $3.507/25/2025IMAImageneBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$25.00 ➝ $23.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/AIMAImageneBio$9.16M3.73N/AN/A$31.33 per share0.27KLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/AXFORX4 Pharmaceuticals$2.56M14.63N/AN/A$3.90 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDWTXDogwood Therapeutics-$12.35M-$18.78N/AN/AN/AN/AN/A-27.41%11/6/2025 (Estimated)IMAImageneBio-$49.23M-$7.68N/AN/AN/AN/A-23.94%-21.62%N/AKLTOKlotho Neurosciences-$6.15M-$0.45N/A∞N/AN/A-325.88%-242.15%N/AXFORX4 Pharmaceuticals-$37.45M-$14.84N/AN/AN/A-311.15%-375.31%-72.87%11/12/2025 (Estimated)Latest DWTX, XFOR, IMA, and KLTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025KLTOKlotho NeurosciencesN/A-$0.12N/A-$0.12N/AN/A8/13/2025Q2 2025DWTXDogwood Therapeutics-$1.26-$1.99-$0.73-$1.99N/AN/A8/8/2025Q2 2025XFORX4 Pharmaceuticals-$4.53-$3.47+$1.06-$3.47$1.62 million$1.97 million7/24/2025Q2 2025IMAImageneBio-$0.14-$0.06+$0.08-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDWTXDogwood TherapeuticsN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDWTXDogwood TherapeuticsN/A7.807.80IMAImageneBioN/A13.5213.52KLTOKlotho NeurosciencesN/A135.73135.73XFORX4 Pharmaceuticals19.103.193.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDWTXDogwood Therapeutics9.05%IMAImageneBio75.00%KLTOKlotho Neurosciences20.07%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipDWTXDogwood Therapeutics3.90%IMAImageneBio5.94%KLTOKlotho Neurosciences26.70%XFORX4 Pharmaceuticals2.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDWTXDogwood Therapeutics51.91 million1.84 millionN/AIMAImageneBio704.02 million3.78 millionNot OptionableKLTOKlotho NeurosciencesN/A61.37 million44.99 millionN/AXFORX4 Pharmaceuticals8011.41 million11.14 millionOptionableDWTX, XFOR, IMA, and KLTO HeadlinesRecent News About These CompaniesX4 Pharmaceuticals announces restructuring, 50% reduction in workforceSeptember 17 at 5:37 PM | msn.comX4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value CreationSeptember 17 at 7:00 AM | globenewswire.comX4 Pharmaceuticals files to sell 59.89M shares of common stock for holdersSeptember 11, 2025 | msn.comX4 Pharmaceuticals Announces Board Resignations and AppointmentsAugust 25, 2025 | msn.comX4 Pharmaceuticals Grants Inducement Equity Awards to New Executive OfficersAugust 15, 2025 | quiverquant.comQX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15, 2025 | globenewswire.comX4 Pharmaceuticals Closes $85M Private Placement DealAugust 14, 2025 | theglobeandmail.comX4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. WainwrightAugust 13, 2025 | msn.comX4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price TargetAugust 13, 2025 | msn.comX4 Pharmaceuticals Announces Closing of Upsized $85 Million Private PlacementAugust 13, 2025 | globenewswire.comX4 Pharmaceuticals announces $60M financing, management changesAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60M Equity FinancingAugust 12, 2025 | msn.comX4 Pharmaceuticals secures $60M PIPE financingAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board LeadershipAugust 12, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Advanced Micro Devices' 2026 Forecasts Are Way Too LowBy Thomas Hughes | September 5, 2025Vanguard’s VUG ETF: The Ultimate Growth ETF for Your PortfolioBy Jeffrey Neal Johnson | September 11, 2025DWTX, XFOR, IMA, and KLTO Company DescriptionsDogwood Therapeutics NASDAQ:DWTX$4.88 -0.02 (-0.31%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.ImageneBio NASDAQ:IMA$8.50 +0.15 (+1.80%) As of 03:33 PM EasternImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.Klotho Neurosciences NASDAQ:KLTO$0.56 -0.01 (-2.61%) As of 03:45 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.X4 Pharmaceuticals NASDAQ:XFOR$3.24 +0.20 (+6.61%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Is Netflix's Ad Deal With Amazon the Catalyst for a New Uptrend? DoorDash Buys Deliveroo: A Game Changer? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
